
This is Medicare fraud capital. Why would Trump give a pass to healthcare exec?
A Miami man whose sentence President Donald Trump commuted this week was accused of helping orchestrate the nation's largest mental healthcare racket before he pleaded guilty to a series of charges in 2011, the Herald reported at the time. Among those charges were defrauding Medicare, healthcare fraud and money laundering.
In South Florida, which carries the disgraceful moniker of America's healthcare fraud capital, holding perpetrators accountable matters. In an administration obsessed with slashing spending and poised to cut food stamps and Medicaid, Trump should have taken the sheer cost of fraud to taxpayers into account.
In 2016, Lawrence Duran — the former co-owner of American Therapeutic Corp., a Miami-based company that ran seven healthcare clinics between South Florida and Orlando — received the longest sentence ever given at the time, 50 years, for Medicare fraud. He and his girlfriend, Marianella Valera, who was released from prison in March 2020, filed 866,000 false claims with Medicare and received more than $87 million, according to court records reviewed by the Herald.
Their case was part of a bigger probe into a scheme involving $200 million in false billings, an amount Trump's DOGE would have bragged about cutting if it meant eliminating foreign aid or the jobs of federal workers.
In all, South Florida was responsible for $308 million, or 20%, of the $1.4 billion in false healthcare claims nationwide in 2021, ranking the region No. 1 in healthcare fraud.
These words by then-Acting U.S. Attorney Tony Gonzalez need attention four years later: '... We are clearly one of the most aggressive offices going after fraudsters. Indeed we are super aggressive in going after all types of healthcare fraud.'
Unfortunately, aggressive prosecution of such cases can be a waste when the president can give sentenced perpetrators a pass.
It's unclear why Trump commuted Duran's sentence, but he was among dozens who received clemency this week. Others include political allies and Trump supporters, a former Chicago gang leader and a former New York representative who pleaded guilty to felony tax evasion in 2014. For example, the daughter of reality TV stars Julie and Todd Chrisley, who received a presidential pardon after their conviction for evading taxes and defrauding banks, is a Trump supporter.
In many cases, it seems Trump's criteria for presidential clemency include how much those under consideration embrace the MAGA label. As Ed Martin, a Trump advisor who led clemency efforts, wrote on social media on Monday: 'No MAGA left behind.' Let's not forget that among those Trump is not leaving behind are the more than 1,500 people pardoned after being convicted for their involvement in the storming of the U.S. Capitol on Jan. 6, 2021, including former Proud Boys leader Enrique Tarrio from Miami.
During Trump's first term, he also commuted the 35-year sentence of Judith Negron, whom a jury convicted in 2011 on 24 counts of conspiracy, fraud, paying kickbacks and money laundering in collaboration with Duran and Valera. Negro was vice president of a company prosecutors say was created to launder $83 million in Medicare payments to Duran, Valera and others. The couple lived in a Miami bayfront condo and drove a Maserati, the Herald reported.
Meanwhile, the scheme prosecutors accused them of orchestrating involved billing Medicare for group mental-health sessions that were not needed or were not provided to patients at their clinics. Those patients were not capable of feeding themselves, much less attending therapy group sessions.
Medicare fraud costs taxpayers a lot of money, both from the fraudulent payments made to providers and for the cost of paying prosecutors and court expenses to bring these cases to justice. Presidential clemency in this case sends the wrong message.
Click here to send the letter.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@

Business Insider
29 minutes ago
- Business Insider
Billionaire GOP megadonor Ken Griffin is confused: Why is the US trying to bring back 'jobs that'll never pay much'?
Ken Griffin had no good answer. The billionaire founder of the $66 billion hedge fund Citadel and its sister company, market maker Citadel Securities, Griffin is a megadonor to the Republican Party and was excited for the American economy after President Donald Trump's election. Less than half a year since Trump's inauguration, Griffin said he was asked during a recent visit to China, "Why are you trying to be like China?" He said there isn't a logical reason the US would want to bring manufacturing "jobs that'll never pay much" to the country, but that seems to be the goal of the tariff policies pursued by Trump's administration. "It's one thing to make Nikes, it's another thing to make F-35 fighters," he said Thursday morning at the Forbes Iconoclast conference in Manhattan. Griffin has been critical of the administration's tariff policies in recent months, calling them a mistake that will hurt the economy and consumers. He said Thursday that they were an "anti-growth agenda," and the expected growth of the US economy has been cut in half since Trump took office. He continued his criticism of Trump, whom he voted for, focusing on the current tax bill, which was passed by the House of Representatives and is now in the Senate. Griffin said it will add "several trillions" of dollars to the deficit and lacks "tough decisions." "The United States' fiscal house is not in order," Griffin said, questioning the decision to cut taxes on small and medium-sized businesses when the deficit was rising. He said credit markets have noted the uncertainty plaguing the US thanks to the administration's policies, noting that "the risk of a US default is priced the same as Italy or Greece." "There's just no words for it," he said. If there was any optimism in his talk, it was about the resilience of American CEOs. He said hiring and capital expenditures will slow as long as there is uncertainty from Washington. Still, he was impressed with how individuals like Doug McMillon, the CEO of Walmart, explained the impact tariffs would have on the consumer. "We should not criticize CEOs for being honest," he said, adding, "shame on the administration" for scolding McMillon and other CEOs for talking about the tariffs' impact. There's still time for Trump and his team to return to pro-growth economic policies, he said, and there's no time to wait. "The United States desperately needs growth" to pay for entitlements like Social Security, he said.


Boston Globe
30 minutes ago
- Boston Globe
What to know about Trump's new travel ban
A full travel ban will affect citizens of the following countries: Afghanistan Chad Republic of Congo Equatorial Guinea Eritrea Haiti Iran Libya Myanmar Somalia Sudan Yemen Partial restrictions will apply to citizens of other countries, meaning they cannot come to the country permanently or apply for certain visas. They are: Burundi Cuba Laos Sierra Leone Togo Turkmenistan Venezuela What is the administration saying? Trump, who announced the ban in a proclamation, said it was intended to protect 'the national security and national interest of the United States and its people.' It is his latest effort to further restrict immigration since returning to office in January, coming after his administration blocked asylum-seekers at the southern border, barred international students from Harvard University and ordered immigration raids across the country. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Cabinet officials in April had identified a list of countries where vetting and screening information surrounding visa applicants was 'deficient' enough to warrant a full or partial suspension, the action said. Advertisement The order accused many countries of the list of exploiting the US visa system and failing to cooperate with the United States on deportations. The action said citizens of some countries had a higher risk of overstaying their visas, which added to burdens on law enforcement agencies. The announcement came days after an Egyptian man who overstayed his visa was arrested in Colorado and charged with attacking a group honoring hostages being held in the Gaza Strip. But Egypt is not subject to the ban. Advertisement What are the exceptions? The new travel ban does not apply to people with visas who are already in the United States, and it includes a few other exemptions. For example, Afghans eligible for the Special Immigrant Visa program, which is for those who helped the US government during the war in Afghanistan, are excepted from the ban. Other exceptions include green card holders, dual citizens and athletes or coaches traveling for a major sporting event held in the United States, like the World Cup or the Olympics. What are the reactions from the banned countries? The announcement provoked swift reaction from some of the affected countries. Venezuela's interior minister, Diosdado Cabello, called the US government 'fascist,' saying that 'being in the United States is a big risk for anybody, not just for Venezuelans.' The African Union released a statement Thursday expressing concern and noting 'the potential negative impact' the move could have on interpersonal relationships, commerce, education and 'diplomatic relations that have been carefully nurtured over decades.' Somalia's ambassador to the United States -- whose country Trump's order labeled a 'terrorist safe haven' -- took a more conciliatory approach. The ambassador, Dahir Hassan Abdi, said in a statement that his government was 'ready to engage in dialogue to address the concerns raised.' The State Department issued about 170,000 visas last year to people from the 12 countries on the list, most of which were nonimmigrant visitor visas for tourism, business or study. That is a small fraction of the millions of visas it issues every year. How does this compare with the last Trump travel ban? In 2017, shortly after taking office, Trump announced a ban on travelers from seven mostly Muslim-majority countries. (Five of those countries are on the list again.) The move, announced in an executive order, took effect immediately and caused chaos, with hundreds of travelers being detained at airports. After a legal battle, the Supreme Court eventually permitted a rewritten ban, and the list of countries later evolved. President Joe Biden ended the ban after taking office. Advertisement The new ban includes countries in more parts of the world and could affect more people than the bans Trump introduced during his first term. This time around, Trump's effort is more likely to withstand legal scrutiny, experts said, partly because of a longer lead-up to the announcement and the range of countries affected.